Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 21, 2018. The report details a regulatory milestone for GSK's respiratory portfolio, specifically regarding the drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol). GSK, in partnership with Innoviva, Inc., announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting an expanded indication for Trelegy Ellipta in the European Union.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory announcement regarding clinical and product development status rather than a financial results report.
Material Changes and Regulatory Developments
- Expanded Indication: The CHMP positive opinion supports using Trelegy Ellipta in a broader group of patients with moderate to severe COPD. Specifically, it targets patients not adequately treated by a long-acting muscarinic receptor antagonist (LAMA) and long-acting beta2-agonist (LABA), in addition to the previously approved indication for patients not adequately treated by an inhaled corticosteroid (ICS) and LABA.
- Clinical Evidence: The recommendation is based on data from the IMPACT study, a landmark trial involving 10,355 patients. The study demonstrated that Trelegy Ellipta was superior to dual therapies (Relvar/Breo Ellipta and Anoro Ellipta) on multiple endpoints, including reducing exacerbations and improving lung function.
- Next Steps: The CHMP opinion is a final step before the European Commission grants a final decision on the regulatory update.
Outlook, Risks, and Management Commentary
Management Commentary: Dr. Hal Barron, GSK's Chief Scientific Officer, emphasized that the expanded indication recognizes the role of Trelegy Ellipta in reducing debilitating exacerbations for patients who continue to experience them despite dual bronchodilator therapies. Dr. Ted Witek of Innoviva welcomed the recognition of the evidence supporting once-daily single inhaler triple therapy.
Risks and Contingencies:
- Regulatory Risk: While the CHMP issued a positive opinion, the final decision rests with the European Commission.
- Safety Profile: The filing includes extensive safety information. Trelegy Ellipta is contraindicated in patients with asthma and is not for acute bronchospasm. Risks include pneumonia, cardiovascular effects (e.g., arrhythmias), paradoxical bronchospasm, and systemic steroid effects. Patients with hepatic impairment, urinary retention, or narrow-angle glaucoma require caution.
- Forward-Looking Statements: GSK and Innoviva caution that actual results may differ materially from projections due to risks and uncertainties, including those described in their respective annual reports.
Key Facts for Investor Verification
- Verify the final approval status of the expanded indication by the European Commission following the CHMP positive opinion.
- Monitor the commercial impact of the expanded indication on Trelegy Ellipta sales in the EU, particularly regarding the new patient population (LAMA/LABA inadequately treated).
- Review the full IMPACT study data published in the New England Journal of Medicine to understand the comparative efficacy against dual therapies.
- Assess the potential for similar regulatory expansions in other global markets based on the IMPACT study data.
- Track the partnership dynamics and royalty revenue implications for Innoviva, Inc., which retains a 15% economic interest in future payments for Trelegy Ellipta.